CLOT+

CanVECTOR

See what CanVECTOR members are publishing to advance the field of venous thromboembolism
Publications since 2016 that are linked to venous thromboembolism and/or anticoagulant therapy

Publications for Agnes Lee

Updated daily

Back to Member List

Show entries

Search:

#	PubMedId	Deleted	Publication
1	39415921	0	Bohm A, Wan BA, Karin A, et al. Antiphospholipid syndrome, monoclonal gammopathy, and cryoglobulinemia overlap leading to recurrent cutaneous microvascular thrombosis: A case report and retrospective cohort study. EJHaem. 2024 Jul 28;5(5):971-975. doi: 10.1002/jha2.987. eCollection 2024 Oct.
2	39299270	0	Lanting V, Takada T, Bosch F, et al. Risk of recurrent venous thromboembolism in patients with cancer: an individual patient data meta-analysis and development of a prediction model. Thromb Haemost. 2024 Sep 19. doi: 10.1055/a-2418-3960.
3	39290989	0	Chornenki NLJ, McPhaden H, Peterson EA, et al. Dual direct oral anticoagulant therapy in challenging thrombosis: a case series. Res Pract Thromb Haemost. 2024 Aug 13;8(6):102546. doi: 10.1016/j.rpth.2024.102546. eCollection 2024 Aug.
4	38964250	0	Stewart KT, Jafari H, Pattillo J, et al. Avoiding the needle: A quality improvement program introducing apixaban for extended thromboprophylaxis after major gynecologic cancer surgery. Gynecol Oncol. 2024 Jul 3;188:131-139. doi: 10.1016/j.ygyno.2024.06.013.
5	38735015	0	Linder M, Ekbom A, Brobert G, et al. Comparison of rivaroxaban and low molecular weight heparin in the treatment of cancer-associated venous thromboembolism: a Swedish national population-based register study. J Thromb Thrombolysis. 2024 May 12. doi: 10.1007/s11239-024-02992-1.
6	38461064	0	Di Nisio M, Lee AY. Direct oral anticoagulants: The new standard of care for cancer associated thrombosis. Eur J Intern Med. 2024 Mar 8:S0953-6205(24)00095-5. doi: 10.1016/j.ejim.2024.03.005.
7	38301711	0	Cohen A, Wallenhorst C, Rivera M, et al. Comparison of Clinical Outcomes in Patients with Active Cancer Receiving Rivaroxaban or Low Molecular Weight Heparin - The OSCAR-UK Study. Thromb Haemost. 2024 Feb 1. doi: 10.1055/a-2259-0662.
8	37757472	0	Navi BB, Zhang C, Kaiser JH, et al. Cancer and the Risk of Perioperative Arterial Ischemic Events. Eur Heart J Qual Care Clin Outcomes. 2023 Sep 26:qcad057. doi: 10.1093/ehjqcco/qcad057.
9	37675613	0	Field TS, Dizonno V, Almekhlafi MA, et al. Study of Rivaroxaban for Cerebral Venous Thrombosis: A Randomized Controlled Feasibility Trial Comparing Anticoagulation With Rivaroxaban to Standard-of-Care in Symptomatic Cerebral Venous Thrombosis. Stroke. 2023 Sep 7. doi: 10.1161/STROKEAHA.123.044113.
10	37583314	0	Caroti KS, Khorana AA, Becattini C, et al. Rivaroxaban Versus Low-Molecular-Weight Heparins in a Broad Cohort of Patients With Cancer-Associated Venous Thromboembolism: An Analysis of the OSCAR-US Program. Clin Appl Thromb Hemost. 2023 Jan-Dec;29:10760296231189282. doi: 10.1177/10760296231189282.

Showing 1 to 10 of 70 entries